Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Triamcinolone Acetonide Cream with Emollient Cream

&times

Overview

What is Dermasorb TA Complete Kit?

The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Triamcinolone acetonide is a member of this class. Chemically triamcinolone acetonide is pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-(11β, 16α) with the empirical formula C24H31O6 and molecular weight 434.50. Its structural formula is:

Each gram of Dermasorb™TA contains 1 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate.



What does Dermasorb TA Complete Kit look like?



What are the available doses of Dermasorb TA Complete Kit?

Sorry No records found.

What should I talk to my health care provider before I take Dermasorb TA Complete Kit?

Sorry No records found

How should I use Dermasorb TA Complete Kit?

Dermasorb™TA is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Topical corticosteroids are generally applied to the affected area as a thin film from two to three times daily depending on the severity of the condition.

Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions.

If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.


What interacts with Dermasorb TA Complete Kit?

Sorry No Records found


What are the warnings of Dermasorb TA Complete Kit?

Sorry No Records found


What are the precautions of Dermasorb TA Complete Kit?

Sorry No Records found


What are the side effects of Dermasorb TA Complete Kit?

Sorry No records found


What should I look out for while using Dermasorb TA Complete Kit?

Dermasorb™TA is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.


What might happen if I take too much Dermasorb TA Complete Kit?

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. See


How should I store and handle Dermasorb TA Complete Kit?

Store at controlled room temperature 20°-25°C (68°-77°F). [See USP.]Dispense in light-resistant containers.Metformin hydrochloride extended-release tablets, USP are manufactured by:Watson Laboratories, Inc.Corona, CA 92880 USADistributed by:Watson Pharma, Inc.Marketed/Packaged by: GSMS Inc. Camarillo, CA 93012Rev. date 05/09                                                                         190733Store at controlled room temperature 20°-25°C (68°-77°F). [See USP.]Dispense in light-resistant containers.Metformin hydrochloride extended-release tablets, USP are manufactured by:Watson Laboratories, Inc.Corona, CA 92880 USADistributed by:Watson Pharma, Inc.Marketed/Packaged by: GSMS Inc. Camarillo, CA 93012Rev. date 05/09                                                                         190733Store at controlled room temperature 20°-25°C (68°-77°F). [See USP.]Dispense in light-resistant containers.Metformin hydrochloride extended-release tablets, USP are manufactured by:Watson Laboratories, Inc.Corona, CA 92880 USADistributed by:Watson Pharma, Inc.Marketed/Packaged by: GSMS Inc. Camarillo, CA 93012Rev. date 05/09                                                                         190733Store at controlled room temperature 20°-25°C (68°-77°F). [See USP.]Dispense in light-resistant containers.Metformin hydrochloride extended-release tablets, USP are manufactured by:Watson Laboratories, Inc.Corona, CA 92880 USADistributed by:Watson Pharma, Inc.Marketed/Packaged by: GSMS Inc. Camarillo, CA 93012Rev. date 05/09                                                                         190733Store at controlled room temperature 20°-25°C (68°-77°F). [See USP.]Dispense in light-resistant containers.Metformin hydrochloride extended-release tablets, USP are manufactured by:Watson Laboratories, Inc.Corona, CA 92880 USADistributed by:Watson Pharma, Inc.Marketed/Packaged by: GSMS Inc. Camarillo, CA 93012Rev. date 05/09                                                                         190733DERMASORB™TA (Triamcinolone Acetonide USP, 0.1%) Cream is supplied in:85.2 g tube NDC 0316-0202-01Rx ONLYPRINTED IN USAP6175.01Manufactured and Distributed by Crown Laboratories, Inc., Johnson City, TN 37604DERMASORB™TA (Triamcinolone Acetonide USP, 0.1%) Cream is supplied in:85.2 g tube NDC 0316-0202-01Rx ONLYPRINTED IN USAP6175.01Manufactured and Distributed by Crown Laboratories, Inc., Johnson City, TN 37604DERMASORB™TA (Triamcinolone Acetonide USP, 0.1%) Cream is supplied in:85.2 g tube NDC 0316-0202-01Rx ONLYPRINTED IN USAP6175.01Manufactured and Distributed by Crown Laboratories, Inc., Johnson City, TN 37604DERMASORB™TA (Triamcinolone Acetonide USP, 0.1%) Cream is supplied in:85.2 g tube NDC 0316-0202-01Rx ONLYPRINTED IN USAP6175.01Manufactured and Distributed by Crown Laboratories, Inc., Johnson City, TN 37604DERMASORB™TA (Triamcinolone Acetonide USP, 0.1%) Cream is supplied in:85.2 g tube NDC 0316-0202-01Rx ONLYPRINTED IN USAP6175.01Manufactured and Distributed by Crown Laboratories, Inc., Johnson City, TN 37604DERMASORB™TA (Triamcinolone Acetonide USP, 0.1%) Cream is supplied in:85.2 g tube NDC 0316-0202-01Rx ONLYPRINTED IN USAP6175.01Manufactured and Distributed by Crown Laboratories, Inc., Johnson City, TN 37604


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions.

The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

Pharmacokinetics

The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses. (See ).

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Non-Clinical Toxicology
Dermasorb™TA is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Use with Other CNS Depressants

If ALPRAZOLAM Tablets are to be combined with other psychotropic agents or anticonvulsant drugs, careful consideration should be given to the pharmacology of the agents to be employed, particularly with compounds which might potentiate the action of benzodiazepines. The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol and other drugs which themselves produce CNS depression.

Use with Imipramine and Desipramine

The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of ALPRAZOLAM Tablets in doses up to 4 mg/day. The clinical significance of these changes is unknown.

Drugs that inhibit alprazolam metabolism via cytochrome P45Q 3A

The initial step in alprazolam metabolism is hydroxylation catalyzed by cytochrome P450 3A (CYP3A). Drugs which inhibit this metabolic pathway may have a profound effect on the clearance of alprazolam (see and for additional drugs of this type).

Drugs demonstrated to be CYP3A inhibitors of possible clinical significance on the basis of clinical studies involving alprazolam (caution is recommended during coadministration with alprazolam).

Fluoxetine—Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.

Propoxyphene—Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%.

Oral Contraceptives—Coadministration of oral contraceptives increased the maximum plasma concentration of alprazolam by 18%, decreased clearance by 22%, and increased half-life by 29%.

Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam).

Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice. Data from studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine. However, data from an drug interaction study involving a single dose of alprazolam 1 mg and steady state dose of sertraline (50 to 150 mg/day) did not reveal any clinically significant changes in the pharmacokinetics of alprazolam. Data from studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine. Caution is recommended during the coadministration of any of these with alprazolam (see ).

Drugs demonstrated to be inducers of CYP3A

Carbamazepine can increase alprazolam metabolism and therefore can decrease plasma levels of alprazolam.

General

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (See ).

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

Information for the Patient

Patients using topical corticosteroids should receive the following information and instructions:

1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.

2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.

3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.

4. Patients should report any signs of local adverse reactions especially under occlusive dressing.

5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:

Burning

Itching

Irritation

Dryness

Folliculitis

Hypertrichosis

Acneiform eruptions

Hypopigmentation

Perioral dermatitis

Allergic contact dermatitis

Maceration of the skin

Secondary infection

Skin Atrophy

Striae

Miliaria

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).